Advancing a new generation of genetic medicines
Designed to move beyond disease management and toward lasting therapeutic impact
TALEN® → Edit
TALEB → Rewrite
TALEM → Reprogram
Targeting the root cause of dislipidemia
Two in vivo gene editing candidates designed to provide durable therapeutic benefit
HEAL-101
APOC3
A TALE-base editor specific for the human APOC3 gene, formulated in lipid nanoparticles (LNP)
For patients with severe hypertriglyceridemia
HEAL-201
PCSK9
A TALE-epigenetic modulator specific for the promotor of the human PCSK9 gene, formulated in LNP
For patients with severe hypercholesterolemia
TALEN®:
For precise gene editing
Our TALEN platform is a highly precise gene editing technology in clinical use, delivering high editing efficiencies with low genotoxicity and off-target effects.
Years of genome engineering expertise
Building the foundation for the next generation of genetic medicines
Patent families
The continued development of our assets is guaranteed by the quality of our science
Genome Engineering Platform
Enabling gene editing, base editing, epigenetic editing and transcriptional regulation
Working with leaders across the field
